Somatic and reproductive outcomes in mice treated with cyclophosphamide in pre-pubertal age

Laura Detti, Daniel C. Martin, Robert Williams, Natalia Schlabritz-Loutsevich, Lucy J. Williams, Rebecca A. Uhlmann

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Disruption in the normal timing of female puberty, such as in pre-pubertal cancer treatments, can cause abnormal somatic development. We sought to evaluate the impact of cyclophosphamide (CTX) on the somatic, uterine, and ovarian, development of pre-pubertal mice. Pre-pubertal (day 18 of life) C57BL/6J female mice were randomized to receive placebo (group 1A and 1B), 200 mg/kg CTX (group 2A), or 120 mg/kg CTX (group 2B). Mice were euthanized on day 56 (A groups) or 95 (B groups) of life. Body weight and length, uterine and ovarian weight and right femur length and weight were measured, and ovarian insufficiency was assessed. Data were analyzed using ANOVA and t-test. Body weight and length did not differ among groups at time of euthanasia. The femur was shorter and weighed less in mice treated with CTX than in controls. Uterine weight was lower in group 2B than 1B (46.1 mg, 95% CI: 42.9-49.4, vs. 62.2 mg, 95% CI: 58.5-65.8, respectively; p = 0.005) and was lower in mice that developed ovarian insufficiency than in mice that did not (p < 0.05). Ovarian weight was lower in mice treated with CTX, regardless of whether they developed ovarian insufficiency. Even with no observable effect on adult body length and weight, CTX treatment in pre-pubertal mice appears to negatively affect femur, uterine, and ovarian development. However, uterine development seems to be dependent on the hormonal status created by CTX more than on its direct effect.

Original languageEnglish (US)
Pages (from-to)140-145
Number of pages6
JournalSystems Biology in Reproductive Medicine
Volume59
Issue number3
DOIs
StatePublished - Jun 1 2013

Fingerprint

Cyclophosphamide
Femur
Weights and Measures
Body Weight
Euthanasia
Puberty
Analysis of Variance
Placebos
Therapeutics
Neoplasms

All Science Journal Classification (ASJC) codes

  • Reproductive Medicine
  • Urology

Cite this

Somatic and reproductive outcomes in mice treated with cyclophosphamide in pre-pubertal age. / Detti, Laura; Martin, Daniel C.; Williams, Robert; Schlabritz-Loutsevich, Natalia; Williams, Lucy J.; Uhlmann, Rebecca A.

In: Systems Biology in Reproductive Medicine, Vol. 59, No. 3, 01.06.2013, p. 140-145.

Research output: Contribution to journalArticle

Detti, Laura ; Martin, Daniel C. ; Williams, Robert ; Schlabritz-Loutsevich, Natalia ; Williams, Lucy J. ; Uhlmann, Rebecca A. / Somatic and reproductive outcomes in mice treated with cyclophosphamide in pre-pubertal age. In: Systems Biology in Reproductive Medicine. 2013 ; Vol. 59, No. 3. pp. 140-145.
@article{39dd24e68b7046dcb654838f34acd0a2,
title = "Somatic and reproductive outcomes in mice treated with cyclophosphamide in pre-pubertal age",
abstract = "Disruption in the normal timing of female puberty, such as in pre-pubertal cancer treatments, can cause abnormal somatic development. We sought to evaluate the impact of cyclophosphamide (CTX) on the somatic, uterine, and ovarian, development of pre-pubertal mice. Pre-pubertal (day 18 of life) C57BL/6J female mice were randomized to receive placebo (group 1A and 1B), 200 mg/kg CTX (group 2A), or 120 mg/kg CTX (group 2B). Mice were euthanized on day 56 (A groups) or 95 (B groups) of life. Body weight and length, uterine and ovarian weight and right femur length and weight were measured, and ovarian insufficiency was assessed. Data were analyzed using ANOVA and t-test. Body weight and length did not differ among groups at time of euthanasia. The femur was shorter and weighed less in mice treated with CTX than in controls. Uterine weight was lower in group 2B than 1B (46.1 mg, 95{\%} CI: 42.9-49.4, vs. 62.2 mg, 95{\%} CI: 58.5-65.8, respectively; p = 0.005) and was lower in mice that developed ovarian insufficiency than in mice that did not (p < 0.05). Ovarian weight was lower in mice treated with CTX, regardless of whether they developed ovarian insufficiency. Even with no observable effect on adult body length and weight, CTX treatment in pre-pubertal mice appears to negatively affect femur, uterine, and ovarian development. However, uterine development seems to be dependent on the hormonal status created by CTX more than on its direct effect.",
author = "Laura Detti and Martin, {Daniel C.} and Robert Williams and Natalia Schlabritz-Loutsevich and Williams, {Lucy J.} and Uhlmann, {Rebecca A.}",
year = "2013",
month = "6",
day = "1",
doi = "10.3109/19396368.2012.751463",
language = "English (US)",
volume = "59",
pages = "140--145",
journal = "Systems Biology in Reproductive Medicine",
issn = "1939-6368",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Somatic and reproductive outcomes in mice treated with cyclophosphamide in pre-pubertal age

AU - Detti, Laura

AU - Martin, Daniel C.

AU - Williams, Robert

AU - Schlabritz-Loutsevich, Natalia

AU - Williams, Lucy J.

AU - Uhlmann, Rebecca A.

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Disruption in the normal timing of female puberty, such as in pre-pubertal cancer treatments, can cause abnormal somatic development. We sought to evaluate the impact of cyclophosphamide (CTX) on the somatic, uterine, and ovarian, development of pre-pubertal mice. Pre-pubertal (day 18 of life) C57BL/6J female mice were randomized to receive placebo (group 1A and 1B), 200 mg/kg CTX (group 2A), or 120 mg/kg CTX (group 2B). Mice were euthanized on day 56 (A groups) or 95 (B groups) of life. Body weight and length, uterine and ovarian weight and right femur length and weight were measured, and ovarian insufficiency was assessed. Data were analyzed using ANOVA and t-test. Body weight and length did not differ among groups at time of euthanasia. The femur was shorter and weighed less in mice treated with CTX than in controls. Uterine weight was lower in group 2B than 1B (46.1 mg, 95% CI: 42.9-49.4, vs. 62.2 mg, 95% CI: 58.5-65.8, respectively; p = 0.005) and was lower in mice that developed ovarian insufficiency than in mice that did not (p < 0.05). Ovarian weight was lower in mice treated with CTX, regardless of whether they developed ovarian insufficiency. Even with no observable effect on adult body length and weight, CTX treatment in pre-pubertal mice appears to negatively affect femur, uterine, and ovarian development. However, uterine development seems to be dependent on the hormonal status created by CTX more than on its direct effect.

AB - Disruption in the normal timing of female puberty, such as in pre-pubertal cancer treatments, can cause abnormal somatic development. We sought to evaluate the impact of cyclophosphamide (CTX) on the somatic, uterine, and ovarian, development of pre-pubertal mice. Pre-pubertal (day 18 of life) C57BL/6J female mice were randomized to receive placebo (group 1A and 1B), 200 mg/kg CTX (group 2A), or 120 mg/kg CTX (group 2B). Mice were euthanized on day 56 (A groups) or 95 (B groups) of life. Body weight and length, uterine and ovarian weight and right femur length and weight were measured, and ovarian insufficiency was assessed. Data were analyzed using ANOVA and t-test. Body weight and length did not differ among groups at time of euthanasia. The femur was shorter and weighed less in mice treated with CTX than in controls. Uterine weight was lower in group 2B than 1B (46.1 mg, 95% CI: 42.9-49.4, vs. 62.2 mg, 95% CI: 58.5-65.8, respectively; p = 0.005) and was lower in mice that developed ovarian insufficiency than in mice that did not (p < 0.05). Ovarian weight was lower in mice treated with CTX, regardless of whether they developed ovarian insufficiency. Even with no observable effect on adult body length and weight, CTX treatment in pre-pubertal mice appears to negatively affect femur, uterine, and ovarian development. However, uterine development seems to be dependent on the hormonal status created by CTX more than on its direct effect.

UR - http://www.scopus.com/inward/record.url?scp=84877276176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877276176&partnerID=8YFLogxK

U2 - 10.3109/19396368.2012.751463

DO - 10.3109/19396368.2012.751463

M3 - Article

VL - 59

SP - 140

EP - 145

JO - Systems Biology in Reproductive Medicine

JF - Systems Biology in Reproductive Medicine

SN - 1939-6368

IS - 3

ER -